Thomas C. Harding
Impact in
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immunology top 5%
- Immunotherapy and Immune Responses
Papers in
- Oncology 31
- PARP inhibition in cancer therapy 17
- CAR-T cell therapy research 6
- Cancer Immunotherapy and Biomarkers 4
-
- CRISPR and Genetic Engineering 7
- RNA Interference and Gene Delivery 5
- Co-authors
- Karin Jooss (10 shared papers)Guang Huan Tu (5 shared papers)Melinda VanRoey (5 shared papers)Andrew D. Simmons (22 shared papers)James B. Uney (5 shared papers)Jianmin Fang (2 shared papers)Kathryn Koprivnikar (5 shared papers)Jingjing Qian (1 shared paper)
- Journals
- Cancer Research (15 papers)Molecular Therapy (3 papers)Molecular Cancer Therapeutics (3 papers)Clinical Cancer Research (2 papers)Nature Biotechnology (2 papers)
- Partner nations
- United StatesUnited KingdomAustralia
In The Last Decade
Thomas C. Harding
49 papers receiving 2.2k citations
Peers
Comparison fields: 5 of 96
- Oncology 951
- Immunology 527
- Genetics 585
- Molecular Biology 1.3k
- Cancer Research 174
Countries citing papers authored by Thomas C. Harding
This map shows the geographic impact of Thomas C. Harding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas C. Harding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas C. Harding more than expected).
Fields of papers citing papers by Thomas C. Harding
This network shows the impact of papers produced by Thomas C. Harding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas C. Harding. The network helps show where Thomas C. Harding may publish in the future.
Co-authors
The 25 scholars most cited alongside Thomas C. Harding, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 49 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2005 | 306 | |
| 2 | 2012 | 290 | |
| 3 | 2005 | 202 | |
| 4 | 2006 | 192 | |
| 5 | 2002 | 172 | |
| 6 | 1998 | 119 | |
| 7 | 2013 | 104 | |
| 8 | 2001 | 101 | |
| 9 | 2007 | 84 | |
| 10 | 2010 | 77 | |
| 11 | 2004 | 53 | |
| 12 | 2018 | 52 | |
| 13 | 1996 | 39 | |
| 14 | 1998 | 36 | |
| 15 | 2006 | 36 | |
| 16 | 2006 | 33 | |
| 17 | 2020 | 33 | |
| 18 | 2018 | 30 | |
| 19 | 2023 | 27 | |
| 20 | 2003 | 27 |
About Thomas C. Harding
Thomas C. Harding is a scholar working on Oncology, Molecular Biology, Genetics, Pulmonary and Respiratory Medicine and Immunology, having authored 49 papers that have together received 2.2k indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (17 papers), Virus-based gene therapy research (10 papers), CRISPR and Genetic Engineering (7 papers), CAR-T cell therapy research (6 papers), RNA Interference and Gene Delivery (5 papers), Toxin Mechanisms and Immunotoxins (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Cancer, Hypoxia, and Metabolism (4 papers). The work is most often cited by research in Oncology (951 citations), Immunology (527 citations), Genetics (585 citations), Molecular Biology (1.3k citations) and Cancer Research (174 citations). Thomas C. Harding has collaborated with scholars based in United States, United Kingdom and Australia. Frequent co-authors include Karin Jooss, Guang Huan Tu, Melinda VanRoey, Andrew D. Simmons, James B. Uney, Jianmin Fang, Kathryn Koprivnikar, Jingjing Qian, Alshad S. Lalani and Bo Luan. Their work appears in journals such as Cancer Research, Molecular Therapy, Molecular Cancer Therapeutics, Clinical Cancer Research and Nature Biotechnology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.